Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Byondis B.V.
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Private-equity firm BC Partners has struck a deal to acquire a majority stake in Synthon International Holding.
Calls are mounting for the EU to make the centralized procedure mandatory for follow-on versions of non‐biological complex drugs and for better regulatory alignment with the US and other countries.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Synthon Biopharmaceuticals B.V.